Precursor Epithelial Subtypes of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasms (A-IPMN): Clinicopathological Features, Recurrence and Response to Adjuvant Chemotherapy.

Adjuvant chemotherapy Epithelial subtypes Gastric IPMN Intestinal Pancreatobiliary Recurrence Survival

Journal

Annals of surgical oncology

ISSN: 1534-4681

Titre abrégé: Ann Surg Oncol

Pays: United States

ID NLM: 9420840

Informations de publication

Date de publication:
03 Jul 2024

Historique:

received: 07 03 2024

accepted: 10 06 2024

medline: 4 7 2024

pubmed: 4 7 2024

entrez: 3 7 2024

Statut: aheadofprint

Résumé

The clinico-oncological outcomes of precursor epithelial subtypes of adenocarcinoma arising from intraductal papillary mucinous neoplasms (A-IPMN) are limited to small cohort studies. Differences in recurrence patterns and response to adjuvant chemotherapy between A-IPMN subtypes are unknown. Clincopathological features, recurrence patterns and long-term outcomes of patients undergoing pancreatic resection (2010-2020) for A-IPMN were reported from 18 academic pancreatic centres worldwide. Precursor epithelial subtype groups were compared using uni- and multivariate analysis. In total, 297 patients were included (median age, 70 years; male, 78.9%), including 54 (18.2%) gastric, 111 (37.3%) pancreatobiliary, 80 (26.9%) intestinal and 52 (17.5%) mixed subtypes. Gastric, pancreaticobiliary and mixed subtypes had comparable clinicopathological features, yet the outcomes were significantly less favourable than the intestinal subtype. The median time to recurrence in gastric, pancreatobiliary, intestinal and mixed subtypes were 32, 30, 61 and 33 months. Gastric and pancreatobiliary subtypes had worse overall recurrence (p = 0.048 and p = 0.049, respectively) compared with the intestinal subtype but gastric and pancreatobiliary subtypes had comparable outcomes. Adjuvant chemotherapy was associated with improved survival in the pancreatobiliary subtype (p = 0.049) but not gastric (p = 0.992), intestinal (p = 0.852) or mixed subtypes (p = 0.723). In multivariate survival analysis, adjuvant chemotherapy was associated with a lower likelihood of death in pancreatobiliary subtype, albeit with borderline significance [hazard ratio (HR) 0.56; 95% confidence interval (CI) 0.31-1.01; p = 0.058]. Gastric, pancreatobiliary and mixed subtypes have comparable recurrence and survival outcomes, which are inferior to the more indolent intestinal subtype. Pancreatobiliary subtype may respond to adjuvant chemotherapy and further research is warranted to determine the most appropriate adjuvant chemotherapy regimens for each subtype.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

Clincopathological features, recurrence patterns and long-term outcomes of patients undergoing pancreatic resection (2010-2020) for A-IPMN were reported from 18 academic pancreatic centres worldwide. Precursor epithelial subtype groups were compared using uni- and multivariate analysis.

RESULTS RESULTS

In total, 297 patients were included (median age, 70 years; male, 78.9%), including 54 (18.2%) gastric, 111 (37.3%) pancreatobiliary, 80 (26.9%) intestinal and 52 (17.5%) mixed subtypes. Gastric, pancreaticobiliary and mixed subtypes had comparable clinicopathological features, yet the outcomes were significantly less favourable than the intestinal subtype. The median time to recurrence in gastric, pancreatobiliary, intestinal and mixed subtypes were 32, 30, 61 and 33 months. Gastric and pancreatobiliary subtypes had worse overall recurrence (p = 0.048 and p = 0.049, respectively) compared with the intestinal subtype but gastric and pancreatobiliary subtypes had comparable outcomes. Adjuvant chemotherapy was associated with improved survival in the pancreatobiliary subtype (p = 0.049) but not gastric (p = 0.992), intestinal (p = 0.852) or mixed subtypes (p = 0.723). In multivariate survival analysis, adjuvant chemotherapy was associated with a lower likelihood of death in pancreatobiliary subtype, albeit with borderline significance [hazard ratio (HR) 0.56; 95% confidence interval (CI) 0.31-1.01; p = 0.058].

CONCLUSIONS CONCLUSIONS

Gastric, pancreatobiliary and mixed subtypes have comparable recurrence and survival outcomes, which are inferior to the more indolent intestinal subtype. Pancreatobiliary subtype may respond to adjuvant chemotherapy and further research is warranted to determine the most appropriate adjuvant chemotherapy regimens for each subtype.

Identifiants

DOI: 10.1245/s10434-024-15677-z PMID: 38961040

pubmed: 38961040

doi: 10.1245/s10434-024-15677-z

pii: 10.1245/s10434-024-15677-z

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Kim HS, Han Y, Kang JS, et al. Fate of patients with intraductal papillary mucinous neoplasms of pancreas after resection according to the pathology and margin status: continuously increasing risk of recurrence even after curative resection suggesting necessity of lifetime surveillance. Ann Surg. 2022. https://doi.org/10.1097/SLA.0000000000004478 .

doi: 10.1097/SLA.0000000000004478 pubmed: 36649067

Wang T, Askan G, Adsay V, et al. Intraductal oncocytic papillary neoplasms: clinical-pathologic characterization of 24 cases, with an emphasis on associated invasive carcinomas. Am J Surg Pathol. 2019. https://doi.org/10.1097/PAS.0000000000001226 .

doi: 10.1097/PAS.0000000000001226 pubmed: 31393268 pmcid: 6786947

Marchegiani G, Mino-Kenudson M, Ferrone CR, Warshaw AL, Lillemoe KD, Fernández-Del Castillo C. Oncocytic-type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis. J Am Coll Surg. 2015. https://doi.org/10.1016/j.jamcollsurg.2015.01.051 .

doi: 10.1016/j.jamcollsurg.2015.01.051 pubmed: 25840549

Kang MJ, Lee KB, Jang JY, Han IW, Kim SW. Evaluation of clinical meaning of histological subtypes of intraductal papillary mucinous neoplasm of the pancreas. Pancreas. 2013. https://doi.org/10.1097/MPA.0b013e31827cddbc .

doi: 10.1097/MPA.0b013e31827cddbc pubmed: 24308063

Distler M, Kersting S, Niedergethmann M, et al. Pathohistological subtype predicts survival in patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg. 2013. https://doi.org/10.1097/SLA.0b013e318287ab73 .

doi: 10.1097/SLA.0b013e318287ab73 pubmed: 23532107

Furukawa T, Hatori T, Fujita I, et al. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut. 2011. https://doi.org/10.1136/gut.2010.210567 .

doi: 10.1136/gut.2010.210567 pubmed: 21193453

Ishida M, Egawa S, Aoki T, et al. Characteristic clinicopathological features of the types of intraductal papillary-mucinous neoplasms of the pancreas. Pancreas. 2007. https://doi.org/10.1097/mpa.0b013e31806da090 .

doi: 10.1097/mpa.0b013e31806da090 pubmed: 18090241

Lucocq J, Hawkyard J, Robertson FP, et al. Risk of recurrence after surgical resection for adenocarcinoma arising from intraductal papillary mucinous neoplasia (IPMN) with patterns of distribution and treatment. Ann Surg. 2023. https://doi.org/10.1097/sla.0000000000006144 .

doi: 10.1097/sla.0000000000006144 pubmed: 37873663

Chong E, Ratnayake B, Dasari BVM, Loveday BPT, Siriwardena AK, Pandanaboyana S. Adjuvant chemotherapy in the treatment of intraductal papillary mucinous neoplasms of the pancreas: systematic review and meta-analysis. World J Surg. 2022. https://doi.org/10.1007/s00268-021-06309-8 .

doi: 10.1007/s00268-021-06309-8 pubmed: 36335279

Chiaro D, Besselink M, Scholten MG, Bruno L. The European study group on cystic tumours of the pancreas. Gut. 2018;67.

Rodrigues C, Hank T, Qadan M, et al. Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. Pancreatology. 2020. https://doi.org/10.1016/j.pan.2020.03.009 .

doi: 10.1016/j.pan.2020.03.009 pubmed: 32332003

Hughes DL, Hughes I, Silva MA. Determining the role of adjuvant therapy in invasive intraductal papillary mucinous neoplasms; a systematic review and meta-analysis. Eur J Surg Oncol. 2022. https://doi.org/10.1016/j.ejso.2022.01.028 .

doi: 10.1016/j.ejso.2022.01.028 pubmed: 35144836

Kobayashi M, Fujinaga Y, Ota H. Reappraisal of the immunophenotype of pancreatic intraductal papillary mucinous neoplasms (IPMNs)-gastric pyloric and small intestinal immunophenotype expression in gastric and intestinal type IPMNs. Acta Histochem Cytochem. 2014. https://doi.org/10.1267/ahc.13027 .

doi: 10.1267/ahc.13027 pubmed: 25221363 pmcid: 4138401

Tanaka M, Fernández-del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017. https://doi.org/10.1016/j.pan.2017.07.007 .

doi: 10.1016/j.pan.2017.07.007 pubmed: 29066391

Nagtegaal ID, Odze RD, Klimstra D, et al. The WHO classification of tumours of the digestive system. Histopathology. 2020. https://doi.org/10.1111/his.13975 .

doi: 10.1111/his.13975 pubmed: 33098683 pmcid: 8048817

Bosman F, Carneiro F, Hruban R, Theise N. WHO Classification of Tumours. Digestive System Tumours. Fifth Edition - WHO - OMS -. Lyon (France): International Agency for Research on Cancer. 2019;1.

Singhi AD, Wood LD, Parks E, et al. Recurrent rearrangements in PRKACA and PRKACB in intraductal oncocytic papillary neoplasms of the pancreas and bile duct. Gastroenterology. 2020. https://doi.org/10.1053/j.gastro.2019.10.028 .

doi: 10.1053/j.gastro.2019.10.028 pubmed: 31678302

AJCC Cancer Staging Manual 8th Edition. In: Definitions. 2020. https://doi.org/10.32388/b30ldk

Rong Y, Wang D, Xu C, et al. Prognostic value of histological subtype in intraductal papillary mucinous neoplasm of the pancreas: a retrospective analysis of outcome from one single center. Medicine. 2017;96(15).

Kim J, Jang KT, Park SM, et al. Prognostic relevance of pathologic subtypes and minimal invasion in intraductal papillary mucinous neoplasms of the pancreas. Tumor Biol. 2011. https://doi.org/10.1007/s13277-010-0148-z .

doi: 10.1007/s13277-010-0148-z

Koh YX, Zheng HL, Chok AY, et al. Systematic review and meta-analysis of the spectrum and outcomes of different histologic subtypes of noninvasive and invasive intraductal papillary mucinous neoplasms. Surgery (United States). 2015. https://doi.org/10.1016/j.surg.2014.08.098 .

doi: 10.1016/j.surg.2014.08.098 pmcid: 4662180

Sadakari Y, Ohuchida K, Nakata K, et al. Invasive carcinoma derived from the nonintestinal type intraductal papillary mucinous neoplasm of the pancreas has a poorer prognosis than that derived from the intestinal type. Surgery. 2010. https://doi.org/10.1016/j.surg.2009.11.011 .

doi: 10.1016/j.surg.2009.11.011 pubmed: 20060146

Nakata K, Ohuchida K, Aishima S, et al. Invasive carcinoma derived from intestinal-type intraductal papillary mucinous neoplasm is associated with minimal invasion, colloid carcinoma, and less invasive behavior, leading to a better prognosis. Pancreas. 2011. https://doi.org/10.1097/MPA.0b013e318214fa86 .

doi: 10.1097/MPA.0b013e318214fa86 pubmed: 21499213

Yamada S, Fujii T, Shimoyama Y, et al. Clinical implication of morphological subtypes in management of intraductal papillary mucinous neoplasm. Ann Surg Oncol. 2014. https://doi.org/10.1245/s10434-014-3565-1 .

doi: 10.1245/s10434-014-3565-1 pubmed: 25515199

Mino-Kenudson M, Fernández-del Castillo C, Baba Y, et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut. 2011. https://doi.org/10.1136/gut.2010.232272 .

doi: 10.1136/gut.2010.232272 pubmed: 21508421

Tanaka M, Fernández-Del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012. https://doi.org/10.1016/j.pan.2012.04.004 .

doi: 10.1016/j.pan.2012.04.004 pubmed: 23561975

Vege SS, Ziring B, Jain R, Moayyedi P. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015. https://doi.org/10.1053/j.gastro.2015.01.015 .

doi: 10.1053/j.gastro.2015.01.015 pubmed: 26584605

McMillan MT, Lewis RS, Drebin JA, et al. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN). Cancer. 2016. https://doi.org/10.1002/cncr.29803 .

doi: 10.1002/cncr.29803 pubmed: 28263387

Ohtsuka T, Fernandez-del Castillo C, Furukawa T, et al. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas. Pancreatology. 2024. https://doi.org/10.1016/j.pan.2023.12.009 .

doi: 10.1016/j.pan.2023.12.009 pubmed: 38182527

Abrams RA, Winter KA, Safran H, et al. Results of the NRG oncology/RTOG 0848 adjuvant chemotherapy question-erlotinib+gemcitabine for resected cancer of the pancreatic head: a phase ii randomized clinical trial. Am J Clin Oncol. 2020. https://doi.org/10.1097/COC.0000000000000633 .

doi: 10.1097/COC.0000000000000633 pubmed: 31985516 pmcid: 7280743

Chen LT. Chemo-radiotherapy in adjuvant therapy of curatively resected pancreatic cancer: lesions from TCOG T3207 Study. Ann Oncol. 2019. https://doi.org/10.1093/annonc/mdz354 .

doi: 10.1093/annonc/mdz354 pubmed: 32067677 pmcid: 6927318

Tempero M, O’Reilly E, Van Cutsem E, et al. LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): updated 5-year overall survival. Ann Oncol. 2021. https://doi.org/10.1016/j.annonc.2021.06.009 .

doi: 10.1016/j.annonc.2021.06.009 pubmed: 33539945

Lucocq J, Hawkyard J, Haugk B, et al. Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia: multicentre ADENO-IPMN study. Br J Surg. 2024;111(4):znae100. https://doi.org/10.1093/bjs/znae100 .

doi: 10.1093/bjs/znae100 pubmed: 38659247

Ghaneh P, Palmer D, Cicconi S, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023. https://doi.org/10.1016/S2468-1253(22)00348-X .

doi: 10.1016/S2468-1253(22)00348-X pubmed: 36521500

Kaiser J, Scheifele C, Hinz U, et al. IPMN-associated pancreatic cancer: survival, prognostic staging and impact of adjuvant chemotherapy. Eur J Surg Oncol. 2022. https://doi.org/10.1016/j.ejso.2021.12.009 .

doi: 10.1016/j.ejso.2021.12.009 pubmed: 35965217

Shimizu T, Akita M, Sofue K, et al. Pancreatobiliary-type intraductal papillary mucinous neoplasm of the pancreas may have 2 subtypes with distinct clinicopathologic and genetic features. Hum Pathol. 2019. https://doi.org/10.1016/j.humpath.2019.05.010 .

doi: 10.1016/j.humpath.2019.05.010 pubmed: 31175918

Tan J, Tan P, Teh BT. Defining the molecular alterations of ampullary carcinoma. Cancer Cell. 2016. https://doi.org/10.1016/j.ccell.2016.01.011 .

doi: 10.1016/j.ccell.2016.01.011 pubmed: 26859450

Hechtman JF, Liu W, Sadowska J, et al. Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). Modern Pathol. 2015. https://doi.org/10.1038/modpathol.2015.57 .

doi: 10.1038/modpathol.2015.57

Perysinakis I, Minaidou E, Leontara V, et al. Differential expression of β-catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2 in intestinal and pancreatobiliary-type ampullary carcinomas. Int J Surg Pathol. 2017. https://doi.org/10.1177/1066896916664987 .

doi: 10.1177/1066896916664987 pubmed: 27543509

Lucocq J, Halle-Smith J. Haugk B et al Long-term Outcomes following resection of adenocarcinoma arising from intraductal papillary mucinous neoplasm (A-IPMN) versus pancreatic ductal adenocarcinoma (PDAC): a propensity-score matched analysis. Ann Surg. 2024. https://doi.org/10.1097/SLA.0000000000006272 .

doi: 10.1097/SLA.0000000000006272 pubmed: 38516777